Shire Mexico – Dr. Raul Vivar, Head of Mexico / Central America and…
The general manager in charge of Mexico, Central America and the Caribbean is on board with the corporate mission of doubling Shire’s product sales to USD 10 billion by 2020…
As one of the world’s leading specialty biopharmaceutical companies, Shire has emerged as a company fully focused on a single purpose: to enable people with life-altering conditions to lead better lives. Today Shire provides treatments in the areas of Neuroscience, Rare Diseases, Gastrointestinal, and Internal Medicine. The company has a portfolio of specialist therapies marketed in over 50 countries worldwide and offices in 29 countries. The company has been present in Mexico since 2008 focusing on lysosomal storage diseases therapies. In the near future the company plans to provide a therapeutic option to patients with hereditary angioedema and start its neuroscience business unit with a product indicated for ADHD (attention deficit hyperactivity disorder).
Address:
Shire Pharmaceuticals Mexico S.A. de C.V Av. Paseo de los Tamarindos 90, Torre 1, Piso 7 Col. Bosques de las Lomas, Del. Cuajimalpa C.P. 05120, México DF MEXICO Tel: +52 (55) 5081 0120 Website: www.shire.com.mxThe general manager in charge of Mexico, Central America and the Caribbean is on board with the corporate mission of doubling Shire’s product sales to USD 10 billion by 2020…
Dr. Teresa Corona Vázquez, the general director of one of the leading neuroscience institutions in Latin America, details their most important research partnerships and achievements, notably with regards to neurodegenerative…
Juan Fransisco Millán Sobaranes of Cetifarma, the council created by the pharmaceutical industry in Mexico for ethics and transparency, discussed the agency’s major milestones and its main priorities for ensuring…
Building on the continuous improvements of the Federal Commission for the Protection Against Sanitary Risk (Cofepris) over the last few years, its recently-appointed Federal Commissioner Julio Sánchez y Tépoz reveals…
Socorro España Lomelí, executive director of Mexico’s National Association of Drug Manufacturers (ANAFAM), details her strategic priorities with regards to the promotion of the industry’s export strategy, the implementation of…
Rafael Gual, general director of CANIFARMA, the chamber that brings together multinational and local drug manufacturers, details how the organization is currently intensifying its efforts to ensure the pharmaceutical industry…
Although the country is moving in the right direction with regards to universal coverage, a number of barriers to effective implementation remain. 57.3 million previously uninsured Mexicans are now enrolled…
PharmaBoardroom spoke to Fabrice Chouraqui, President of Novartis Latin America and Canada at the Financial Times LatAm Healthcare & Life Sciences Summit in September 2015. He emphasizes the criticality of…
Two companies from two different countries chose Mexico as their entry market to Latin America. The heads of these companies spoke to PharmaBoardroom about their market entry strategies. Edmée Stenken,…
The industry of medical devices is soaring in Mexico. The general manager of ConvaTec discusses strategic priorities, new approaches and how reduced time to market is feeding the double-digit growth…
IMS Health recently released its World Review 2015. The new general manager of North Latin America shares the company’s assessment on the performance of the Mexican pharmaceutical market for 2014,…
The industry of medical devices is still not very well understood. Pablo Dávila shared with us his overview on the Mexican market, how the Mexican Association of Innovative Medical Device…
The technical & RA director and the managing director of Qually Corporacion explain how authorized third partied act as an extension of the regulative body, Cofepris, helping to assure that…
See our Cookie Privacy Policy Here